Joseph W. Polli

Rational Use of in Vitro P-glycoprotein Assays in Drug Discovery

Joseph W. Polli, Stephen A. Wring, Joan E. Humphreys et al. · Journal of Pharmacology and Experimental Therapeutics · 2001 · 658 citations

Passive Permeability and P-Glycoprotein-Mediated Efflux Differentiate Central Nervous System (CNS) and Non-CNS Marketed Drugs

Kelly M. Mahar Doan, Joan E. Humphreys, Lindsey O. Webster et al. · Journal of Pharmacology and Experimental Therapeutics · 2002 · 623 citations

IN VITRO P-GLYCOPROTEIN INHIBITION ASSAYS FOR ASSESSMENT OF CLINICAL DRUG INTERACTION POTENTIAL OF NEW DRUG CANDIDATES: A RECOMMENDATION FOR PROBE SUBSTRATES

Jarkko Rautio, Joan E. Humphreys, Lindsey O. Webster et al. · Drug Metabolism and Disposition · 2006 · 259 citations

An Unexpected Synergist Role of P-Glycoprotein and Breast Cancer Resistance Protein on the Central Nervous System Penetration of the Tyrosine Kinase Inhibitor Lapatinib (N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016)

Joseph W. Polli, Katie Olson, John P. Chism et al. · Drug Metabolism and Disposition · 2008 · 249 citations

The Role of Efflux and Uptake Transporters in N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, Lapatinib) Disposition and Drug Interactions

Joseph W. Polli, Joan E. Humphreys, Kelly A. Harmon et al. · Drug Metabolism and Disposition · 2008 · 248 citations